Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children
Background: Ceftazidime-Avibactam (CAZ-AVI) plays a key role in the treatment of Multidrug Resistant Gram-Negative Bacilli (MDR-GNB) infections. In pediatrics, CAZ-AVI is clinically approved for treatment of urinary tract or intra-abdominal infection. However, there is limited data available about i...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2025-03-01
|
| סדרה: | Brazilian Journal of Infectious Diseases |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S1413867025000182 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
